YahooOctober 23, 2026 at 10:36 AM NY4 Days Ago
BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential?
Bristol Myers edges out AbbVie with a cheaper valuation and higher dividend yield, but pipeline execution, legacy drug declines and debt remain key risks.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
